Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 4/20 | 0.36 |
| ▸ | RORC | P51449 | 4/20 | 0.34 |
| ▸ | DGAT2 | Q96PD7 | 7/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | ACACA | Q13085 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26565190 | 0.90 | LTB4R (0.36) | LTB4RRORCDGAT2AKR1C3AKR1C2 | |
| SCHEMBL26565316 | 0.85 | LTB4R (0.33) | LTB4RRORCDGAT2AKR1C3AKR1C2 | |
| SCHEMBL26565169 | 0.84 | LTB4R (0.35) | LTB4RRORCDGAT2AKR1C3AKR1C2 | |
| SCHEMBL26565274 | 0.84 | LTB4R (0.37) | LTB4RDGAT2ACACATP53 | |
| SCHEMBL26565302 | 0.81 | PKM (0.35) | LTB4RDGAT2AKR1C3AKR1C2TP53 | |
| SCHEMBL26565543 | 0.79 | DGAT2 (0.33) | DGAT2AKR1C3AKR1C2TP53 | |
| SCHEMBL26565273 | 0.77 | RORC (0.51) | RORC | |
| SCHEMBL26565186 | 0.77 | LTB4R (0.38) | LTB4RDGAT2AKR1C3AKR1C2TP53 | |
| SCHEMBL26565239 | 0.74 | LTB4R (0.38) | LTB4RDGAT2AKR1C3AKR1C2TP53 | |
| SCHEMBL26565167 | 0.73 | LTB4R (0.39) | LTB4RAKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018011-B2 | Macrocyclic compounds and compositions, and methods of preparing and using the same | KURA ONCOLOGY, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230322711-A1 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | WUXI APPTEC (HONG KONG) LIMITED (CN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018011-B2 | Macrocyclic compounds and compositions, and methods of preparing and using the same | FNTA, FDPS, GGPS1 | LTB4R 2287/4885RORC 612/4885DGAT2 902/4885 |
| US-20230322711-A1 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | FNTA, FDPS, GGPS1 | LTB4R 2287/4885RORC 612/4885DGAT2 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.